

# Anticancer property of anthracycline cf. curcumin

P M Chincholikar<sup>1\*</sup>, S Amlathe<sup>2</sup>

<sup>1</sup>Department of Chemistry, Nri Institute of Information Science and Technology, Bhopal, Madhya Pradesh, INDIA.

<sup>2</sup>HOD, Department of Chemistry, UIT, BU Campus, Bhopal, Madhya Pradesh, INDIA.

Email: [pmc76@rediffmail.com](mailto:pmc76@rediffmail.com), [samlathe97@gmail.com](mailto:samlathe97@gmail.com)

## Abstract

As a part of our research in generating a good drug model with high anticancer efficiency. We had compared the anticancer properties of Anthracycline (potent antibiotic used in chemotherapy) and Curcumin (an edible, non-toxic component of turmeric). The study shows that the effective ways of anticancer activities are totally different. The Anthracyclines contribute to anticancer activity by inhibition of DNA replication process, while Curcumin has its effects through different biological pathways. Here we are presenting a comparative account of both the compounds with their structural data details- that were studied. It has been found that Anthracyclines have high toxic effects but have high potency; Curcumin being less toxic has potency but has low bio-availability.

**Key Words:** Anthracycline, Curcumin, Anticancer Activity.

## \*Address for Correspondence:

Dr. P. M. Chincholikar, Department of Chemistry, Nri Institute of Information Science and Technology, Bhopal, Madhya Pradesh, INDIA.

Email: [pmc76@rediffmail.com](mailto:pmc76@rediffmail.com)

Access this article online	
Quick Response Code:	Website: <a href="http://www.statperson.com">www.statperson.com</a>
	Accessed Date: 26 March 2018

## INTRODUCTION

Curcumin is produced from the turmeric plant *Curcuma longa*, it is an alkaloid. This plant is a member of the ginger family (Zingiberaceae). Since ancient times *curcuma longa* is an integral part of Indian culture and tradition. It is the ancient herb used in culinary practices of India. Historically, the turmeric has been used as a major component of Indian Ayurvedic medicine to treat a wide variety of health problems<sup>1</sup>. Current researchers have identified that it is the molecule responsible for the biological activity of turmeric. Chemically, Curcumin molecules are polyphenols that impart the yellow color of turmeric. These molecules exist in two tautomeric forms, keto and enol<sup>2</sup>. Structurally, there are several functional groups, carbonyl groups that form a diketone and aromatic ring systems<sup>3</sup>. The medicinal properties of Curcumin is being investigated by Clinical trials on humans to analyse the effects on various diseases viz., Alzheimer's disease, multiple myeloma, myelodysplastic syndromes, psoriasis, colon cancer, pancreatic cancer, and, recently on deadliest Swine flu<sup>4-5-6-7</sup>.




Figure 1:

**Anthracycline (daunomycin):** Anthracyclines ( anthracycline antibiotics) are a class of drugs (CCNS or cell-cycle non-specific)[8] used in cancer chemotherapy derived from *Streptomyces* bacterium *Streptomyces peucetius var.caesius*.<sup>9</sup> These compounds are used to treat many cancers, including leukemias, lymphomas, breast, uterine, ovarian, and lung cancers. The anthracyclines are among the most effective anticancer treatments ever developed and are effective against more types of cancer than any other class of chemotherapeutic agents.<sup>8,9,10</sup> Their main adverse effect is cardiotoxicity, which considerably limits their usefulness. Use of anthracyclines has also been shown to be significantly associated with cycle 1 severe or febrile neutropenia.<sup>11</sup> Other adverse effects include vomiting, severe headache, alopecia, etc. The first anthracycline discovered was daunorubicin (trade name Daunomycin), which is produced naturally by *Streptomyces peucetius*, a species of actinobacteria. Doxorubicin (trade name Adriamycin) was developed shortly after, and many other related compounds have followed, although few are in clinical use.<sup>12</sup> Cancer patients who are undergoing chemotherapy have an increased risk of developing cardiovascular complications, and the risk is even greater if there is a known history of heart disease. Among the serious clinical cardiac complications that have been reported are: Arrhythmias, Myocardial necrosis causing a dilated cardiomyopathy, Vaso-occlusion or vasospasm resulting in angina or myocardial infarction.<sup>13</sup> The family of anthracyclines includes over 2,000 known analogs. There are several anthracycline anti-cancer drugs, and many of the newer, synthetic versions were developed in the hopes of diminishing the cardiotoxicity while maintaining effectiveness. The following are mostly commonly used in cancer treatment today: To analyze different potential drug molecules the quantitative structure-activity relationship (QSAR) method is a useful approach. QSAR which is helpful to explain how structural features in a drug molecule influence the biological activities, its analysis also gathers information that is very useful for molecular dynamics, medicinal Chemistry and drug design. Hence, correlating the physicochemical properties or structural features of the important compounds with their biological activity is essential. studies in QSAR were according to Lipinski rule of 5<sup>14,15,16</sup>. The bio activity analysis of a drug, provides a successful low cost *in-silico* based QSAR evaluation<sup>17</sup>. The partition coefficient is a ratio of concentrations of un-ionized compound between the two solutions. To measure the partition coefficient of ionizable solutes, the pH of the aqueous phase is adjusted such that the predominant form of the compound is un-ionized. The logarithm of the ratio of the concentrations of the un-ionized solute in the solvents is called log *P*: The log *P* value is also known as a measure of lipophilicity<sup>18</sup>.

$$\log P_{\text{oct/wat}} = \log \left( \frac{[\text{solute}]_{\text{octanol}}}{[\text{solute}]_{\text{water}}^{\text{un-ionized}}} \right)$$

Figure 2:

The drug's distribution coefficient strongly affects the ease of any drug that can reach its intended target in the body and how strong an effect it will have once it reaches its target, and how long it will remain in the body in an active form. Log*P* is one criterion used in medicinal chemistry to assess the druglikeness of a given molecule, and used to calculate lipophilic efficiency, a function of potency and Log*P* that evaluate the quality of research compounds[19][20]. For any given compound lipophilic efficiency is defined as the p*IC*<sub>50</sub> (or p*EC*<sub>50</sub>) of interest minus the Log*P* of the compound. Here we have used 20 different curcumin analogues to study their log*P* characters. Experimental determination of log *P*<sub>o/w</sub> is often complex and time consuming and can be done only for already synthesized compounds. Thus we have adapted a number of computational methods for the prediction of the parameter that have been proposed. In our work a QSAR study is performed, models of related the structures of a heterogeneous group of 31 drug compounds were developed and their *n*-octanol–water partition coefficients were studied. Finally, the accuracy of the proposed model was illustrated using the following: leave one out, bootstrapping and external test set, cross-validations and Y-randomisation techniques<sup>21-22</sup>.

**Experimental section:** The molecular structure of Curcumin and anthracycline derivatives were collected from Pubchem database available in the NCBI server (<http://pubchem.ncbi.nlm.nih.gov/>). The structure were drawn by ACD chemsketch tool (<http://www.acdlabs.com>) and corresponding logP of each structure was obtained. DRAGON and GAUSSIAN 05 were used for the descriptor study<sup>23-28,32</sup>.

**Data set:** The properties data used in this study are the LogP<sub>o/w</sub> of the set of 20 curcumin derivatives<sup>37-49</sup>. The data set was randomly divided into two subsets: the training set containing 20 Compounds (80%) and the test set containing compounds (20%). A regression model was built using training set, and the test set was used to evaluate the predictive ability of the model obtained. The properties data for the complete sets of compounds are presented in Table 2, to derive QSAR models, an appropriate representation of the chemical structure was necessary. For this purpose, the descriptors that were commonly used for the structure are shown in table-1.

**Table-1:** The descriptors used in the present study

<i>Descriptors</i>	<i>Symbol</i>	<i>Abbreviation</i>
<i>Quantum chemical descriptors</i>	<i>Natural Population Analysis</i>	<i>NPA</i>
	<i>Electrostatic potential</i>	<i>EP</i>
	<i>Molecular Dipole Moment</i>	<i>MDP</i>
	<i>Molecular Polarizability</i>	<i>MP</i>
	<i>Highest Occupied Molecular Orbital</i>	<i>HOMO</i>
	<i>Lowest Unoccupied Molecular Orbital</i>	<i>LUMO</i>
	<i>difference between LUMO and HOMO</i>	<i>E GAP</i>
	<i>Electro negativity [<math>\chi = -1/2 (HOMO - LUMO)</math>]</i>	<i>X</i>
	<i>EI Electro philicity (<math>\omega = \chi / 2 \eta</math>)</i>	<i><math>\Omega</math></i>
	<i>Mulliken GAPCharge</i>	<i>MC</i>
<i>Chemical properties</i>	<i>Partition Coefficient</i>	<i>Log P</i>
	<i>Hydration Energy</i>	<i>HE</i>
	<i>Refractivity</i>	<i>REF</i>
	<i>Molecule surface area</i>	<i>MSA</i>
	<i>Mass</i>	<i>M</i>
	<i>Molecule volume</i>	<i>V</i>

**Data:** All logP<sub>o/w</sub> data for all 31 compounds was taken from the literature. The data set was split into a training set (20compounds) and a prediction set (11 compounds). The log P<sub>o/w</sub> of these compounds are deposited in Journal log as supporting material (see Tables 2). Chemical structure of drugs that illustrated in this study is shown in Table 2.

**Molecular descriptor generation:** All of the molecules were drawn into the Chemsketch. The Gaussian 03 and DRAGON packages were used for calculating the molecular descriptors (Table 1). Some of the descriptors are obtained directly from the chemical structure, e. g. constitutional, geometrical, and topological descriptors. Other chemical and physicochemical properties were determined by the chemical structure (lipophilicity, hydrophilicity descriptors, electronic descriptors, energies of interaction). In this work, we used Gaussian 03 for ab initio calculations. DFT method at 6-31G\* were applied for optimization of anti-cancer drugs and calculation of many of the descriptors. software hyper

Chem and some of the descriptors such as partition coefficient, surface area, hydration energy, and refractivity were calculated through it. The rest of the descriptors were obtained of Gaussian calculations. A large number of descriptors were calculated by Gaussian package and ACDCHEMsketch5.0 software. One way to avoid data redundancy is to exclude descriptors that are highly intercorrelated with each other before performing statistical analysis. The molecular structures were saved by the HIN extension and entered on the DRAGON software for the calculation of the 18 different types of theoretical descriptors for each molecule. They included (a) 0D-constitutional (atom and group counts); (b) 1D-functional groups, 1D-atom centered fragments; (c) 2D-topological, 2DBCUTs, 2D-walk and path counts, 2D-autocorrelations, 2D-connectivity indices, 2D-information indices, 2D-topological charge indices, and 2D-eigenvalue-based indices; and (d) 3D-Randic molecular profiles from the geometry matrix, 3D-geometrical, 3D-WHIM, and 3DGETAWAY descriptors. A stepwise technique was employed that only one parameter at a time was added to a model and always in the order of most significant to least significant in terms of F-test values. Statistical parameters were calculated subsequently for each step in the process, so the significance of the added parameter could be verified. The goodness of the correlation is tested by the regression coefficient ( $R^2$ ), the F-test and the standard error of the estimate (SEE). The test and the level of significance, as well as the confidence limits of the regression coefficient, are also reported. The squared correlation coefficient,  $R^2$ , is a measure of the fit of the regression model. Correspondingly, it represents the part of the variation in the observed (experimental) data that is explained by the model.

**Genetic algorithm for descriptor selection:** Genetic algorithm variable selection is a technique that helps identify a subset of the measured variables that are, for a given problem, the most useful for a precise and accurate regression model. The selection of relevant descriptors, which relate the  $\log Po/w$  to the molecular structure, is an important step to construct predictive models. The genetic algorithm was applied to the input set of 53 molecular descriptors for each chemical of the studied data sets and the related response, in order to extract the best set of molecular descriptors, which are, in combination, the most relevant variables in modeling the response of the training set chemicals. Genetic algorithm (GA), included in the PLS Toolbox version 2.0, was used for variables selection (based on the training set). Using GA-based MLR variable selection procedures, the dependent variables, i.e., the  $\log Po/w$ , were used to find subsets of molecular descriptors that provide a good relationship to the  $\log Po/w$ . Given an X-matrix of descriptors data and a  $\log Po/w$  of values to be predicted, one can choose a random subset of variables from  $\mathbf{X}$  and, through the use of cross-validation and MLR regression method, determine the root-mean-square error of cross-validation (RMSECV)[31,33] obtained when using only that subset of variables in a regression model. Genetic algorithms use this approach iteratively to locate the variable subset (or subsets) which gives the lowest RMSECV. The first step of the GA is to generate a large number (e.g., 32, 64, 128) of random selections of the variables and calculate the RMSECV for each of the given subsets. Each subset of variables is called an individual (or chromosome) and the yes/no flags indicating which variables are used by that individual is the gene for that individual. The pool of all tested individuals is the population. The RMSECV values, described as the fitness of the individual, indicate how predictive each individual's selection of variables is for the  $\log Po/w$ <sup>39</sup>. The diversity of the training set and the test set was analyzed using the principal component analysis (PCA) method<sup>40,41</sup>. The PCA was performed with the calculated structure descriptors for the whole data set to detect the homogeneities in the data set<sup>42</sup>, and also to show the spatial location of the samples to assist the separation of the data into the training and test sets. The PCA results showed that three principal components (PC1 and PC2) described 24.39% of the overall variables, as follows: PC1 = 16.79% and PC2 = 7.6%. Since almost all the variables can be accounted for by the first three PCs, their score plot is a reliable representation of the spatial distribution of the points for the data set. The multi-collinearity between the above seven descriptors were detected by calculating their variation inflation factors (VIF)<sup>43-45</sup>, which can be calculated as follows:

$$VIF = \frac{1}{1 - r^2}$$

where  $r$  is the correlation coefficient of the multiple regression between the variables in the model. If VIF equals to 1, then no inter-correlation exists for each variable; if VIF falls into the range of 1–5, the related model is acceptable; and if VIF is larger than 10, the related model is unstable and a recheck is necessary. The corresponding VIF values of the seven descriptors are shown in Table 2. As can be seen from this table, most of the variables had VIF values of less than 5, indicating that the obtained model has statistical significance. To examine the relative importance as well as the contribution of each descriptor in the model, the value of the mean effect (ME)<sup>[46-50]</sup> was calculated for each descriptor. This calculation was performed with the equation below:

$$\frac{B \sum_{i=1}^n d_{ij}}{\sum_{j=1}^m B_j \sum_{i=1}^n B_{ij}}$$

MF<sub>j</sub>= Where MF<sub>j</sub> represents the mean effect for the considered descriptor *j*, β<sub>j</sub> is the coefficient of the descriptor *j*, d<sub>ij</sub> stands for the value of the target descriptors for each molecule and, eventually, *m* is the descriptors number for the model. The MF value indicates the relative importance of a descriptor, compared with the other descriptors in the model. Its sign indicates the variation direction in the values of the activities as a result of the increase (or reduction) of the descriptor values. The mean effect values are shown in Table 2.

**Table 2: The linear model based on the eight parameters selected by the GA-MLR method**

Descriptor	Chemical meaning	MF <sub>a</sub>	VIF <sub>b</sub>
Constant	Intercept	0	0
EP26	Electrostatic potential 26	1.260265	1.148737
NPA13	Natural population analysis 13	-0.15876	1.182888
SAPAC22	Surface area approx atomic charg22	0.00414	1.105926
PW3	Path/walk3-randic shape index	-0.07902	1.284402
Mor16m	3D-MorSE-signal16/weighted by atomic masses	0.005628	1.321815
Mor18m	3D-MorSE-signal18/weighted by atomic masses	0.002912	1.105745
Mor24m	3D-MorSE-signal24/weighted by atomic masses	-0.00102	1.226363
G2u1st component symmetry directional WHIM index/unweighted		-0.03414	1.099806

*a*Mean effect  
*b*Variation inflation factors

All descriptors were calculated for the neutral species. The log *Po/w* is assumed to be highly dependent upon the EP26, NPA13, SAPAC22, PW3, Mor16m, Mor18m, Mor24m and G2u. In the present study, the QSAR model was generated using a training set of 33 molecules (Table 2). The test set of 8 molecules (Table 2) with regularly distributed log *Po/w* values was used to assess the predictive ability of the QSAR models produced in the regression. Multiple linear regression analysis provided a useful equation that can be used to predict the log *Po/w* of drug based upon these parameters. The best equation obtained for the lipophilicity of the curcumin compounds is LogP=150.269(±37.396)-12.787(±2.570)EP26+3.882(±0.762)NPA13+0.097(±0.025)SAPAC22+30.446(±9.409)PW3+1.056(±0.236)Mor16m+0.445(±0.168)Mor18m-1.418(±0.258)Mor24m+34.976(±7.513)G2u  
 N=31 N train=20 N test=11 R<sup>2</sup> train=0.893 F train=24.934 R<sup>2</sup> test=0.541 F test=-0.045 R<sup>2</sup> adj= 0.857 Q<sup>2</sup> LOO=0.816 Q<sup>2</sup> LGO=0.730.


In this equation, N is the number of compounds; R<sup>2</sup> is the squared correlation coefficient, Q<sup>2</sup> LOO, Q<sup>2</sup> LGO are the squared cross-validation coefficients for leave one out, bootstrapping and external test set respectively, F is the Fisher F statistic. The figures in parentheses are the standard deviations. The built model was used to predict the test set data and the prediction results are given in Table 1. As can be seen from Table 1, the calculated values for the LogP are in good agreement with those of the experimental values. The predicted values for LogP for the compounds in the training and test sets using equation 1 were plotted against the experimental LogP values in Figure 1.

**Table 3: Anthracycline QSAR equation generated for various analogues**

QSAR EQUATION	R <sup>2</sup>	Q <sup>2</sup>	F-value
Activity = 0.3807 - 65.932*Relative number of double bonds + 293+.83 *G1m + 0.35987*L1s - 24.212*BELe4 - 118.49R2u	0.8684	0.6925	18.47
Activity = 25.013 - 34.382* BELp4 - 213.72* R2u+ + 299.01*G1m + 320.86* FPSA - 3 Fractional PPSA (PPSA -3 / TMSA) (Zefirov's PC) - 0.057943* count of H- donor sites(Zefirov's PC)	0.8652	0.7061	17.98
Activity = -27.557 - 8.3335 * BELp4 - 98.687* R2u+ + 333.47*G1m +	0.8632	0.6853	17.67

293.91 * FPSA - 3 Fractional PPSA (PPSA-3 / TMSA) (Zefirov's PC) - 0.0027580 * piPC09	0.8601	0.6823	17.22
Activity = -27.557 - 8.3335 * BELp4 - 98.687 * R2u+ + 333.47 * G1m + 293.91 * FPSA - 3 Fractional PPSA (PPSA - 3 / TMSA) (Zefirov's PC) - 0.0027580 * piPC09	0.8494	0.6869	15.80
Activity = 113.44 - 59.835 * BELp4 - 214.82 * R2u+ - 0.32843 * RDF090m + 0.33288 * RDF115m + 0.15807 * RDF065v	0.8483	0.6809	15.65
Activity = 255.27 - 1.3648 * number of double bonds + 363.20 * G1m - 76.706 * BEHv1 + 0.37471 * L1m +24.694 * Max partial charge for a C atom (Zefirov's P C)	0.8469	0.6388	15.49
Activity = 119.41 - 74.363 * BELp4 - 231.69 * R2u+ + 275.01 * G1m - 9.7538 * R5e + 0.077463 * MOR02e	0.8466	0.7062	15.45
Activity = 123.91 - 5.7533 * BELp4 - 123.28 * R2u+ + 362.95 * G1m + 312.56 * FPSA - 3 Fractional PPSA (PPSA - 3/ TMSA) (Zefirov's PC) - 40.584 * BEHm1			

Activity = - 131.10 - 1.4841 \* Number of double bonds + 544.85 \* G1m + 0.8446 0.6320 15.22 0.50181 \* Ts + 1.1407 \* HOMA + 183.12 \* X2A Activity = -13.838  
+1.6716 \* BELp4 - 159.72 \* R2u+ + 335.96 \* G1m + 302.82 \* FPSA - 3 Fractional PPSA (PPSA - 3/ TMSA) (Zefirov's PC) - 20.568 \* BELe4




**Figure 3:** The predicted values for LogP for the compounds in the training and test sets using equation 1 were plotted against the experimental LogP values

Also, in order to assess the robustness of the model, the Y-randomisation test was applied in this study<sup>25-28</sup>. The dependent variable vector (LogP) was randomly shuffled and The new QSAR models (after several repetitions) would be expected to have low  $R^2$  and  $Q^2_{LOO}$  values (Table 4). If the opposite happens then an acceptable QSAR model cannot be obtained for the specific modeling method and data.

**Table 3:** The  $R^2_{train}$  and  $Q^2_{LOO}$  values after several Y-randomisation tests

No	$Q^2$	$R^2$
1	0.113284	0.472045
2	0.048896	0.230775
3	0.003785	0.234683
4	0.012186	0.31958
5	0.042953	0.180091
6	0.042723	0.320828
7	0.019219	0.21774
8	0.083071	0.279033
9	0.005137	0.320529



The MLR analysis was employed to derive the QSAR models for different Nucleoside analogues. MLR and correlation analyses were carried out by the statistics software SPSS (Table 4). Figure 2 has showed that results were obtained from equation HF/6-31G\*16 the experimental values.

**Table 4:** The correlation coefficient existing between the variables used in different MLR and equations with HF/6-31G\* method

	EP26	NPA13	SAPAC22	PW3	Mor16m	Mor18m	Mor24m	G2u
EP26	1	0	0	0	0	0	0	0
NPA13	0.054065	1	0	0	0	0	0	0
SAPAC22	-0.2344	-0.12944	1	0	0	0	0	0
PW3	0.012593	0.236561	-0.34562	1	0	0	0	0
Mor16m	-0.33313	-0.24288	-0.00361	-0.23044	1	0	0	0
Mor18m	0.177918	0.081215	-0.13201	0.061633	-0.19956	1	0	0
Mor24m	0.157028	0.378326	-0.18368	0.073222	-0.35014	0.252322	1	0
G2u	.047641	0.049852	-0.17016	0.322559	-0.04335	0.01788	-0.08377	1

**Interpretation of descriptors:** The QSAR developed indicated that electrostatic properties (EP), natural population analysis (NPA), surface area approx atomic charge 22 (SAPAC), Path/walk3-randic shape index(PW3) 3D-MoRSE-signal [16,18,24] /weighted by atomic masses (Mor16m,Mor18m, Mor24m), 1<sup>st</sup> component symmetry directional WHIM index/unweighted (G2u)drug *n*-octanol/water partition coefficients. Positive values in the regression coefficients indicate that the indicated descriptor contributes positively to the value of log *P*<sub>o/w</sub>, whereas negative values indicate that the greater the value of the descriptor the lower the value of log *P*<sub>o/w</sub>. In other words, increasing the EP26 and Mor24m will decrease log *P*<sub>o/w</sub> and increasing the NPA13,SAPAC22,PW3,Mor16m,G2u and Mor18m increases extent of log *P*<sub>o/w</sub> of the curcumin. The standardized regression coefficient reveals the significance of an individual descriptor presented in the regression model.

**Series 1:** the values of log *P* were obtained by using prediction.

**Series 2:** the values of log *P* were obtained by using Experimental methods

**Figure 3.** The comparison between biological activity (log *p*) using experimental and prediction

The greater the absolute value of a coefficient, the greater the weight of the variable in the model. Mor16m is the fourth descriptor, appearing in the model. It is one of the 3D-molecule representations of structures based on electron diffraction (3D-MoRSE) descriptors. The 3DMoRSE descriptors are derived from infrared spectral simulation using a generalised scattering function<sup>31</sup>. This descriptor was proposed as signal (16, 24)/weighted by the atomic masses which relates to the atomic masses of the molecule. The Mor(16,24)m displays a positive sign, which indicates that the Log*P*<sub>o/w</sub> is directly related to this descriptor. The next descriptor is the path/walk 3Randic shape index (PW3), which is one of the topological descriptors. The atomic path/walk indices are defined for each atom as the ratio between the atomic path count and the atomic walk count of the same length. Whereas the number of paths in a molecule is bounded and determined by the molecule's diameter, the number of walks is unbounded. However, being interested only in quotients, the walk count is terminated when it exceeds the maximum allowed length of the corresponding path<sup>31</sup>. The molecular path/walk indices are defined as the average sum of atomic path/walk indices of equal length. As the path/walk count ratio is independent of molecular size, these descriptors can be considered as shape descriptors. As is apparent from Table 2, the PW3 mean effect has a negative sign which indicates that the Log*P*<sub>o/w</sub> is inversely related to this descriptor; therefore, increasing the PW3 of molecules leads to a decrease in its Log*P*<sub>o/w</sub> values.

## CONCLUSION

In this article, a QSAR study of anthracycline and curcumin analogues was performed based on the theoretical molecular descriptors calculated by the DRAGON and GAUSSIAN software and selected. The built model was assessed

comprehensively (internal and external validation) and all the validations indicated that the QSAR model built was robust and satisfactory, and that the selected descriptors could account for the structural features responsible for the anti-cancer drugs activity of the compounds. Though the bioavailability aspects of curcumin is still a challenge. The QSAR model developed in this study can provide a useful tool to predict the activity of new compounds and also to design new compounds with high activity.

## REFERENCES

1. Aggarwal BB; Sundaram C; Malani N; Ichikawa H. *Adv. Exp. Med. Biol.* 2007, 595: 1–75.
2. Tsonko M. Kolev; Evelina A.; Velcheva; Bistra A; Stamboliyska; Michael Spitteller. *International Journal of Quantum Chemistry*, 2005, 102 (6), 1069–79.
3. Albená T.; Dinkova-Kostova; Paul Talalay *Carcinogenesis*, 1999, 20 (5), 911-914.
4. Aggarwal BB; Shishodia S. *Biochemical Pharmacology*, 2006, 71 (10), 1397–1421.
5. Hyunsung Choi; Yang-Sook Chun; Seung-Won Kim; Myung-Suk Kim; Jong-Wan Park. *Molecular Pharmacology*, 2006, 70 (5), 1664–71.
6. Hatcher H; Planalp R; Cho J; Torti FM; Torti SV. *Cell. Mol. Life Sci.*, 2008, 65 (11), 1631–1652.
7. Da-Yuan Chen ; Jui-Hung Shien ; Laurence Tiley ; Shyan-Song Chiou ; Sheng-Yang Wang; Tien-Jye Chang ; Ya-Jane Lee ; Kun-Wei Chan ; Wei-Li Hsu. *FoodChemistry*, 2010, 119 (4), 1346– 1351.
8. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings". *Adv. Drug Deliv. Rev.* 46 (1-3): 3–26. 2001. doi:10.1016/S0169-409X(00)00129-0. PMID 11259830.
9. Lipinski CA "Lead- and drug-like compounds: the rule-of-five revolution". *Drug Discovery Today: Technologies* 1(4): 337–341. 2004. doi:10.1016/j.ddtec.2004.11.007.
10. Oprea TI, Davis AM, Teague SJ, Leeson PD. "Is there a difference between leads and drugs? A historical perspective". *J Chem Inf Comput Sci* 41 (5):30815.2001) doi: 10.1021/ci010366a. PMID 11604031.
11. Edwards MP, Price DA (2010). "Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks". *Annual Reports in Medicinal Chemistry. Annual Reports in Medicinal Chemistry* 45: 381–391. doi:10.1016/S0065-7743(10)45023-X. ISBN 978-0-12-380902-5.
12. Jump up Leeson PD, Springthorpe B (November 2007). "The influence of drug-like concepts on decision-making in medicinal chemistry". *Nat Rev Drug Discov* 6 (11): 881 90. doi:10.1038/nrd2445. PMID 17971784.
13. David A. Winkler. *Briefings in Bioinformatics*, 2002, 3(1), 73-86.
14. Schuettelkopf AW; D.M.F VanAalten. *Acta Crystallographica*, 2004, D60: 1355-1363.
15. David J.; Wild J. *Chem. Inf. Model*, 2005, 459(1), 212
16. Andrews PR; Craik DJ; Martin JL. *J Med Chem.* 1984, 27(12), 1648-1657.
17. [www.pubchem.com](http://www.pubchem.com)
18. Shahlai M; Fassihi A; Saghaie L. *Eur J Med Chem.*, 2010, 45(4), 1572-1582.
19. Zahra Garkani-Nejad; Fereshteh Saneie. *Bull. Chem. Soc. Ethiop.*, 2010, 24(3), 317-325.
20. Du Q, Mezey PG; Chou KC. *J Comput Chem.*, 2005, 26(5):461-470.
21. Brockmann, H., [Anthracyclonones and Anthracyclines. (Rhodomycinone, Pyrromycinone and Their Glycosides)]. *Fortschr Chem Org Naturst*, 1963. 21: p. 121-82.
22. *Anthracycline Chemistry and Biology: Biological Occurrence and Biosynthesis, Synthesis and Chemistry: No. 1.* 1 (9 July 2008) ed. *Topics in Current Chemistry*, ed. K. Krohn: Springer. [www.wikipedia.com](http://www.wikipedia.com)
23. <http://www.pfeist.net/ALL/anth.html>
24. <http://cmbi.bjmu.edu.cn>
25. <http://toxipedia.org>
26. Chaires, J.B., N. Dattagupta, and D.M. Crothers, Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. *Biochemistry*, 1982. 21(17): p. 3933-40.
27. Krueger, W.C., et al., The interaction of nogalamycin and analogs with DNA and other biopolymers. *Chem Biol Interact*, 1981. 36(1): p. 1-18.
28. Gniazdowski, M., et al., Effects of anticancer drugs on transcription factor-DNA interactions. *Expert Opin Ther Targets*, 2005. 9(3): p. 471-89.
29. Mansilla, S. and J. Portugal, Sp1 transcription factor as a target for anthracyclines: effects on gene transcription. *Biochimie*, 2008. 90(7): p. 976-87.
30. Guano, F., et al., Topoisomerase poisoning activity of novel disaccharide anthracyclines. *Mol Pharmacol*, 1999. 56(1): p. 77-84.
31. Gille, L. and H. Nohl, Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. *Free Radic Biol Med*, 1997. 23(5): p. 775-82.

Source of Support: None Declared  
Conflict of Interest: None Declared